miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.

por Guinn, Daphne, Ruppert, Amy S., Maddocks, Kami, Jaglowski, Samantha, Gordon, Amber, Lin, Thomas S., Larson, Richard, Marcucci, Guido, Hertlein, Erin, Woyach, Jennifer, Johnson, Amy J., Byrd, John C.
Publicado 2014

Mass Cytometry as a Tool for Investigating Senescence in Multiple Model Systems

por Abdul-Aziz, Amina, Devine, Raymond D., Lyberger, Justin M., Chang, Hsiaochi, Kovacs, Amy, Lerma, James R., Rogers, Andrew M., Byrd, John C., Hertlein, Erin, Behbehani, Gregory K.
Publicado 2023

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

por Chen, Timothy L., Harrington, Bonnie, Truxall, Jean, Wasmuth, Ronni, Prouty, Alexander, Sloan, Shelby, Lehman, Amy M., Sampath, Deepa, Orlemans, Eric, Baiocchi, Robert A., Alinari, Lapo, Byrd, John C., Woyach, Jennifer A., Hertlein, Erin
Publicado 2021

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion

por Eisenmann, Eric D., Stromatt, Jack C., Fobare, Sydney, Huang, Kevin M., Buelow, Daelynn R., Orwick, Shelley, Jeon, Jae Yoon, Weber, Robert H., Larsen, Bill, Mims, Alice S., Hertlein, Erin, Byrd, John C., Baker, Sharyn D.
Publicado 2022

Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia

por Kämpjärvi, Kati, Järvinen, Tiina M., Heikkinen, Tuomas, Ruppert, Amy S., Senter, Leigha, Hoag, Kevin W., Dufva, Olli, Kontro, Mika, Rassenti, Laura, Hertlein, Erin, Kipps, Thomas J., Porkka, Kimmo, Byrd, John C., de la Chapelle, Albert, Vahteristo, Pia
Publicado 2014

Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia

por Chen, Timothy L., Gupta, Nikhil, Lehman, Amy, Ruppert, Amy S., Yu, Lianbo, Oakes, Christopher C., Claus, Rainer, Plass, Christoph, Maddocks, Kami J., Andritsos, Leslie, Jones, Jeffery A., Lucas, David M., Johnson, Amy J., Byrd, John C., Hertlein, Erin
Publicado 2016

Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study

por Bhatnagar, Bhavana, Kohlschmidt, Jessica, Orwick, Shelley J., Buelow, Daelynn R., Fobare, Sydney, Oakes, Christopher C., Kolitz, Jonathan E., Uy, Geoff, Stock, Wendy, Powell, Bayard L., Nicolet, Deedra, Hertlein, Erin K., Mrózek, Krzysztof, Blachly, James S., Eisfeld, Ann-Kathrin, Baker, Sharyn D., Byrd, John C.
Publicado 2023

The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia

por Miller, Cecelia R., Ruppert, Amy S., Fobare, Sydney, Chen, Timothy L., Liu, Chaomei, Lehman, Amy, Blachly, James S., Zhang, Xiaoli, Lucas, David M., Grever, Michael R., Tallman, Martin S., Flinn, Ian W., Rassenti, Laura Z., Kipps, Thomas J., Sampath, Deepa, Coombes, Kevin R., Hertlein, Erin K.
Publicado 2017

Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia

por Elgamal, Ola A., Mehmood, Abeera, Jeon, Jae Yoon, Carmichael, Bridget, Lehman, Amy, Orwick, Shelley J., Truxall, Jean, Goettl, Virginia M., Wasmuth, Ronni, Tran, Minh, Mitchell, Shaneice, Lapalombella, Rosa, Eathiraj, Sudharshan, Schwartz, Brian, Stegmaier, Kimberly, Baker, Sharyn D., Hertlein, Erin, Byrd, John C.
Publicado 2020

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia

por Fobare, Sydney, Kohlschmidt, Jessica, Ozer, Hatice Gulcin, Mrózek, Krzysztof, Nicolet, Deedra, Mims, Alice S., Garzon, Ramiro, Blachly, James S., Orwick, Shelley, Carroll, Andrew J., Stone, Richard M., Wang, Eunice S., Kolitz, Jonathan E., Powell, Bayard L., Oakes, Christopher C., Eisfeld, Ann-Kathrin, Hertlein, Erin, Byrd, John C.
Publicado 2022

Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease

por Hertlein, Erin, Beckwith, Kyle A., Lozanski, Gerard, Chen, Timothy L., Towns, William H., Johnson, Amy J., Lehman, Amy, Ruppert, Amy S., Bolon, Brad, Andritsos, Leslie, Lozanski, Arletta, Rassenti, Laura, Zhao, Weiqiang, Jarvinen, Tiina M., Senter, Leigha, Croce, Carlo M., Symer, David E., de la Chapelle, Albert, Heerema, Nyla A., Byrd, John C.
Publicado 2013

TP-0903 is active in models of drug-resistant acute myeloid leukemia

por Jeon, Jae Yoon, Buelow, Daelynn R., Garrison, Dominique A., Niu, Mingshan, Eisenmann, Eric D., Huang, Kevin M., Zavorka Thomas, Megan E., Weber, Robert H., Whatcott, Clifford J., Warner, Steve L., Orwick, Shelley J., Carmichael, Bridget, Stahl, Emily, Brinton, Lindsey T., Lapalombella, Rosa, Blachly, James S., Hertlein, Erin, Byrd, John C., Bhatnagar, Bhavana, Baker, Sharyn D.
Publicado 2020

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia

por Goswami, Swagata, Mani, Rajeswaran, Nunes, Jessica, Chiang, Chi-Ling, Zapolnik, Kevan, Hu, Eileen, Frissora, Frank, Mo, Xiaokui, Walker, Logan A., Yan, Pearlly, Bundschuh, Ralf, Beaver, Larry, Devine, Raymond, Tsai, Yo-Ting, Ventura, Ann, Xie, Zhiliang, Chen, Min, Lapalombella, Rosa, Walker, Alison, Mims, Alice, Larkin, Karilyn, Grieselhuber, Nicole, Bennett, Chad, Phelps, Mitch, Hertlein, Erin, Behbehani, Gregory, Vasu, Sumithira, Byrd, John C., Muthusamy, Natarajan
Publicado 2022